News
RVVTF
0.022
NaN%
--
Revive Therapeutics Eyes FDA Approval for COVID Treatment
TipRanks · 1d ago
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. Has submitted a Type C meeting request package to the U.S. Food & Drug Administration for the evaluation of a proposed clinical study of Bucillamine. The Company expects to hear from the FDA on a firm date for the meeting. Revive is a specialty life sciences company.
Barchart · 1d ago
Weekly Report: what happened at RVVTF last week (0318-0322)?
Weekly Report · 3d ago
Revive Therapeutics Advances Bucillamine for Long COVID
TipRanks · 03/19 11:38
Weekly Report: what happened at RVVTF last week (0311-0315)?
Weekly Report · 03/18 10:42
Revive Therapeutics Researches Bucillamine Uses
TipRanks · 03/12 11:38
Weekly Report: what happened at RVVTF last week (0304-0308)?
Weekly Report · 03/11 10:40
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation. U.S. FDA issued breakthrough therapy designation for its LSD formulation for generalized anxiety disorder. After the announcement, Mind Medicine stock surged 55% to reach a new 52-week high. Other companies focused on psychedelic drugs also traded higher on Thursday.
Seeking Alpha · 03/07 16:29
Weekly Report: what happened at RVVTF last week (0226-0301)?
Weekly Report · 03/04 10:42
Oregon House passes bill to end hard drug decriminalization
New Zealand this week reversed a ban on tobacco sales to younger generations. Thailand just announced that it would ban the use of recreational cannabis by the end of this year. Oregon is getting second thoughts on decriminalizing hard drugs. The first U.S. State to decriminalize hard drugs has declared a fentanyl state of emergency.
Seeking Alpha · 03/01 11:42
Revive Therapeutics Finalizes Private Funding
TipRanks · 02/26 21:48
Weekly Report: what happened at RVVTF last week (0219-0223)?
Weekly Report · 02/26 10:52
Weekly Report: what happened at RVVTF last week (0212-0216)?
Weekly Report · 02/19 10:54
Psychedelic stocks gain after FDA priority review for MDMA therapy
Psychedelic stocks gain after FDA priority review for MDMA therapy. If approved, MDMA could become the first psychedelic-assisted therapy. The new drug application seeks approval of MDMA for post-traumatic stress disorder. The FDA has set a target action date of August 11, 2024 for its review.
Seeking Alpha · 02/12 17:13
Weekly Report: what happened at RVVTF last week (0205-0209)?
Weekly Report · 02/12 10:45
Weekly Report: what happened at RVVTF last week (0129-0202)?
Weekly Report · 02/05 10:52
Weekly Report: what happened at RVVTF last week (0122-0126)?
Weekly Report · 01/29 10:44
Revive Therapeutics announces offering of up to $3 million
Revive Therapeutics announces offering of up to $3 million Jan. 25, 2024 4:10 AM ETRevive Therapedutics Ltd. (RVVTF) Stock. Revive TherAPEutics announced a private placement of a maximum of 85,714,285 units at a price of $0.035 per unit.
Seeking Alpha · 01/25 09:10
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
Barchart · 01/24 16:55
Weekly Report: what happened at RVVTF last week (0115-0119)?
Weekly Report · 01/22 10:47
More
Webull provides a variety of real-time RVVTF stock news. You can receive the latest news about Revive Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About RVVTF
Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.